Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer

PURPOSE: Etirinotecan pegol (NKTR-102) is a unique, long-acting topoisomerase-I inhibitor with prolonged systemic exposure to SN38 (7-ethyl-10-hydroxycamptothecin), the active metabolite of irinotecan. This randomized phase II trial investigated two dosing schedules of etirinotecan pegol in patients...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Vergote, Ignace B., Garcia, Agustin, Micha, John, Pippitt, Charles, Bendell, Johanna, Spitz, Daniel, Reed, Nicholas, Dark, Graham, Fracasso, Paula M., Ibrahim, Emad N., Armenio, Vincent A., Duska, Linda, Poole, Chris, Gennigens, Christine, Dirix, Luc Y., Leung, Abraham C.F., Zhao, Carol, Soufi-Mahjoubi, Raoudha, Rustin, Gordon
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2013
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878105/
https://ncbi.nlm.nih.gov/pubmed/24081946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.45.1278
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares